10/2/2013 6:40:10 AM
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported that results from the company’s STEPS 2 study of GATTEX® (teduglutide) in patients with Short Bowel Syndrome (SBS) were accepted for presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course in San Diego, California, October 11-16, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by